Newsfeeds - Spark Newswire

3 minute read

Pfizer, Beam Enter Exclusive Multi-Target Research Collaboration To Advance Novel In Vivo Base Editing Programs For A Range Of Rare Diseases; Beam Will Receive An Upfront Payment Of $300M, Be Eligible To Receive Future Milestone Payments Of Up To $1.05…

Today, 2:37 PM

Pfizer Inc. (NYSE:PFE) and Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year research collaboration focused

BEAM

3 minute read

Beam Therapeutics Announced Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones Said First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of S…

By Charles Gross

Today, 2:37 PM

Beam Therapeutics Inc.

BEAM

1 minute read

Guggenheim Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $130

By Benzinga Newsdesk

Today, 2:37 PM

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $130.

BEAM

5 minute read

Events
News

Beam Therapeutics Outlined Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provided Preclinical Data Updates at ASH 2021

By Charles Gross

Today, 2:37 PM

Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a three-stage, long-term development strategy for its base editing approach to treat sickle cell disease (SCD).

BEAM

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG

By Benzinga Newsdesk

Today, 2:37 PM

Intellia Therapeutics (NTLA) 2U (TWOU) Veracyte (VCYT) Beam Therapeutics (BEAM) Materialise (MTLS) Proto Labs (PRLB) TuSimple Holdings (TSP) Archer Aviation (ACHR) Velo3d (VLD) Splunk (SPLK) The Walt Disney

ACHR

1 minute read

SVB Leerink Maintains Outperform on Beam Therapeutics, Lowers Price Target to $116

By Benzinga Newsdesk

Today, 2:37 PM

SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $117 to $116.

BEAM

2 minute read

Earnings

Looking Into Beam Therapeutics’s Return On Capital Employed

By Benzinga Insights

Today, 2:37 PM

Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a loss of $69.63 million.

BEAM

1 minute read

Beam Therapeutics Q3 EPS $(0.42) Up From $(0.69) YoY

By Benzinga Newsdesk

Today, 2:37 PM

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.42) per share. This is a 39.13 percent increase over losses of $(0.69) per share from the same period last year.

BEAM

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Nov. 3, 2021

By Benzinga Newsdesk

Today, 2:37 PM

Zoom Video (ZM) Exact Sciences (EXAS) Twilio (TWLO) Robinhood (HOOD) UIPath (PATH) DraftKings (DKNG) Intellia Therapeutics (NTLA) Beam Therapeutics (BEAM) Teladoc (TDOC) NIU Technologies

ADPT

1 minute read

Cathie Wood’s ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM

By Benzinga Newsdesk

Today, 2:37 PM

Intellia Therapeutics (NTLA) - 34,200 Pacific Biosciences of California (PACB) - 119,183 Archer Aviation (ACHR) - 591,618 MarkForged Holding Corp (MKFG) - 76,612 Blade

ACHR